3sbio, Inc. · HKEX:1530
3sbio — J.P. Morgan 2026 Healthcare Conference
30 slides from 3sbio's conference presentation, Jan 15, 2026
Slide 1: Corporate Presentation
Corporate Presentation J.P. Morgan 2026 Healthcare Conference Tony He (hexiang@3sbio.com) Chief Financial Officer January 15th, 2026 San Francisco, California
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Where We Are Today
Where We Are Today 24.5% 30+ 7 50+ 35th 2013-2024 Revenue CAGR Disclosed Pipelines Plants in 6 Cities Worldwide Approved Products China's Top 100 Pharmaceutical Companies 9+ bn ~800 High Standard ~3,000 MSCI China Index Revenue 2024FY R&D Professionals Manufacturing Sales Professionals Included in A
Slide 4: Key Milestones in 2025
Key Milestones in 2025 705 (PD1/HER2 BsAb) 707 (PD1/VEGF BsAb) TPIAO ® was Oncology 707 PhII POC data was 707 for 1L PDL1+ NSCLC Entered into license initiated Ph II for solid License agreement for published Ph II data for recommended for Paclitaxel oral solution included in granted BTD by NMPA agre
Slide 5: Expanding Commercialized Products
Expanding Commercialized Products Oncology /Hematology Nephrology Autoimmune Dermatology EPIAO&SEPO® TPIAO® Global exclusive No.1 market share commercialized among rhEPO1 rhTPO Cipterbin® 1st launched Xenopax® Chinese HER2 mAb Yisaipu® Mandi® 1st launched Chinese CD25 mAb TNFα fusion protein injecti
Slide 6: More to Expect in 2026
More to Expect in 2026 Expect 3 NMEs approved, 2+ NDAs submitted in 2026 Hematology/ Oncology Dermatology/ Nephrology Autoimmune Metabolism Long-acting rhEPO Q3W Paclitaxel oral IL17A mAb | PsO Semaglutide CKD anemia anticipated approval solution IL1β mAb | AG Anticipated NDA submission Anticipated
Slide 7: Accelerate International Footprints
Accelerate International Footprints 4 10+ 35+ 70% products sold international GMP covered international YOY revenue from overseas certificates markets overseas 25H1 • EPIAO • GMP system of • ~60 SKUs obtained marketing • Outstanding quality of • Yisaipu manufacture plant approval document from 20+ d
Slide 8: Partnership with Pfizer
Partnership with Pfizer 707: PD-1&VEGF Bispecific Antibody A Potential Next-generation I/O Therapy 1.25 Bispecific Antibody with Tetravalent Structure: US$bn 4.8 Double +Each “arm” can bind both -Digit 100 up to 150 PD-1 and VEGF US$mn US$bn US$mn Up-front Payment Milestone Payment Royalty Share Pur
Slide 9: Near-Term 707 MRCT Trials
Near-Term 707 MRCT Trials Phase 1 Phase 2 Phase 3 Phase 3 1L Sq&Nsq NSCLC1 Thoracic Phase1/2: NSCLC4 Combinations with ADC Phase 2/3: 1L ES-SCLC3 GI Phase1/2: la/mHCC5 Phase 3: 1LmCRC2 Phase1/2: la/mUC GU Phase1/2: la/mRCC6 1. https://clinicaltrials.gov/study/NCT07222566; 2. https://clinicaltrials.g
Slide 10: Manufacturing Base of Large-scale DS and DP Global Supply
Supply Rights Outside of the US FDA&EMA GMP standard 01 • Manufacture, examination, storage fully automated intelligent factory • FDA GMP standard Manufacturing Base of 75,000L+ biologics DS capacities 02 • 6*12,000L stainless steel bioreactors; Large-scale DS and DP • 3*1000L disposable bioreactors
Slide 11: Revenue Momentum Expected to Continue
Revenue Momentum Expected to Continue 2025 est. 2026-2029 est. 2030~ est. New Launches Next Wave Innovation Long-acting EPO 705, 706, 708, 709, SSS40, IL-17A, IL-1β, IL-4Rα, IL-5 mAbs SPGL008, SSS59, 626, 627 HER2 ADC2, Clifutinib3… and more Combined Development, regulatory Double-digit royalties, u
Slide 12: Selected Pipeline of Oncology / Hematology
Selected Pipeline of Oncology / Hematology Code Molecule Indication Pre-IND Phase I Phase II Phase III NDA SSS40 NGF mAb Cancer pain with bone metastases 705 PD1/HER2 BsAb HER2+ solid tumor Only actively ongoing clinical trial in China Advanced NSCLC 706 PD1/PDL1 BsAb Advanced gastrointestinal tumor
Slide 13: 705: Anti-PD-1/HER2 BsAb for Pan-HER2 Expressing Tumors (Ph II)
705: Anti-PD-1/HER2 BsAb for Pan-HER2 Expressing Tumors (Ph II) • 705 connects ScFv of anti-PD1 to the heavy chain Fc segment of Trastuzumab through 705 GGGGS, and simultaneously inhibits PD-1/PD-L1 and HER2 signaling pathway • Combines targeted therapy and immune therapy to achieve better tumor imm
Slide 14: 706: Anti-PD-1/PD-L1 BsAb Targeting Pan-tumors (Ph II)
706: Anti-PD-1/PD-L1 BsAb Targeting Pan-tumors (Ph II) 706 706 demonstrated superior T-cell activation ✓ Efficacy and Safety Signals compared to parent anti-PD-1 or anti-PD-L1 mono and the combination • Preliminary efficacy signals observed with 706 monotherapy across multiple tumor types, including
Slide 15: SSS59: Anti-MUC17/CD3/CD28 TsAb for Gastrointestinal Tumors (Ph I)
SSS59: Anti-MUC17/CD3/CD28 TsAb for Gastrointestinal Tumors (Ph I) SSS59 ✓ MOA • SSS59 represents an enhanced T-cell engager (TCE) that incorporates both primary CD3 activation and secondary CD28 co-stimulation within a single Anti-MUC17/CD3/CD28 trispecific Ab molecular construct, eliciting sustain
Slide 16: SPGL008: Anti-B7H3 Ab/IL15Rα sushi-IL15 FP (Ph I)
SPGL008: Anti-B7H3 Ab/IL15Rα sushi-IL15 FP, Targeting Pan-tumor (Ph I) SPGL008 ✓ MOA • SPGL008 is a bifunctional molecule in which an anti-B7H3 monoclonal antibody with a novel structure and sequence is conjugated to IL-15Rα B7H3 Ab/IL15Rα sushi-IL15 FP sushi-IL-15. The cytokine component is linked
Slide 17: SSS57: A Long-acting ActRIIB-Ig Trap for Blood Disease (Pre-IND)
SSS57: A Long-acting ActRIIB-Ig Trap for Blood Disease (Pre-IND) SSS57 • No animal deaths or moribund states were observed. SSS57 demonstrated its good safety profile in monkeys • S.C. t1/2：238~258h Long-acting ActRIIB-Ig Trap • In the 0.4 mg/kg and 2 mg/kg groups, no test article- • The subcutaneou
Slide 18: Selected Pipeline of Nephrology
Selected Pipeline of Nephrology Biopharmaceuticals Renal Anemia with NDA Accepted Maintenance Dialysis SSS06 Phase II/III Long-acting rhEPO Cancer Related Anemia (CIA) Fill the gap in domestic long-acting Q3W erythropoietin Once every three weeks SSS55 Paroxysmal Nocturnal More indications Hemoglobi
Slide 19: SSS17: Optimized Choice for CKD Anemia and POA Patients (Ph II)
SSS17: Optimized Choice for CKD Anemia and POA Patients (Ph II) HIF inhibitor: Inhibiting PH enzyme activity, blocking degradation effects on hypoxia-inducible factor (HIF), enhancing HIF-α levels, thereby SSS17 promotes the synthesis of key proteins such as erythropoietin (EPO) and treats renal ane
Slide 20: SSS55: A Novel C3b-targeting Bifunctional Fusion Protein (Ph I)
SSS55: A Novel C3b-targeting Bifunctional Fusion Protein (Ph I) SSS55 inhibited all three complement pathways more strongly than the benchmark SSS55 C3b-targeting Bifunctional FP Affinity maturation SSS55 exhibited potent efficacies in a periodontitis model in monkeys Probing pocket depth change Ble
Slide 21: Selected Pipeline of Autoimmune
Selected Pipeline of Autoimmune Code Molecule Indication Pre-IND Phase I Phase II Phase III NDA Moderate-to-severe PsO 608 IL17A mAb AS Nr-axSPA AG 613 IL1β mAb PGF Adult AD monotherapy Adult AD with TCS Adolescent AD 611 IL4Rα mAb Pediatric AD AD full population coverage CRSwNP COPD 610 IL5 mAb EA
Slide 22: 626: 2nd Generation BDCA2 mAb for SLE (Ph Ib/II)
626: 2nd Generation BDCA2 mAb for SLE (Ph Ib/II) SSGJ-626 Huge Unmet Medical Needs Through inhibiting plasmacytoid dendritic cell MoA (pDC), the secretion of IFNα was inhibited. Thus regulating the activity of a range of immune cells Strong BDCA2 affinity ( KD: 2.48E-11) Degree of Very high (There w
Slide 23: 627: TL1A mAb for IBD, Potential BIC (Ph I)
627: TL1A mAb for IBD, Potential BIC (Ph I) TL1A —A Breakthrough Target for Inflammatory Bowel Disease (IBD) Treatment: Clinical Modality Target Representative Drug Indications Characteristics MOA Status Small Molecule JAK1 Upadacitinib Ph3 CD Short half-life, drug resistance TNF-a Adalimumab Approv
Slide 24: 716: Potential Global FIC BsAb for AD Treatment (US&CN IND Submitted)
716: Potential Global FIC BsAb for AD Treatment (US&CN IND Submitted) Efficacy in vitro greatly surpassed the benchmarks 250000 0.9 inhibition inhibition Signaling Inhibition Cytokine secretion Inhibition 716 1276 1396 - 716 200000 1276 0.8 - 716 - 716 1396 - 716 benchmark B 150000 benchmark A OD450
Slide 25: Mandi: A Leading Specialized Consumer Pharmaceuticals Company
Mandi: A Leading Specialized Consumer Pharmaceuticals Company • A leading specialized consumer pharmaceuticals company in • Mandi (蔓迪® ) as China the market leader in • Dedicated to developing and China’s consumer delivering comprehensive and healthcare market long-term solutions for skin for hair h
Slide 26: Mandi: Online and Offline Network and Financial Performance
Comprehensive User Reach Layout and Industry-leading Digital Health Management Platform Financial Performance Traditional E-commerce Medical Institutions · Tmall 100 Mn CNY Revenue 2,000+ · JD 12.3 14.6 9.8 7.4 Offline Network Online Network 6.2 Social Media · PDD · Douyin Mall 2022 2023 2024 2024H1
Slide 27: BD & M&A Strategy
BD & M&A Strategy Sufficient Financial R&D Support Resource Near 800 scientists, accounting for over Strong cash flow generation 20% of total staff; R&D expense ratio capacity surpass 10% Flexible Collaboration Structures Manufacturing Capabilities License-in, CSO, CDMO, license-out, 6 manufacturin
Slide 28: 2026 Catalysts
2026 Catalysts ◆ PD1/VEGF - Clinical Progress of Global Phase IIIs ◆ PD1/VEGF - Data Maturity from Ongoing China Trials ◆ Data Disclosure - 705 / 706 / 008 / 59 ◆ Continuous NMEs and NDAs Approvals ◆ EPS Accretive Investments ◆ Consumer Health Spin-off 28
Slide 29: Q&A
Q&A 29
Slide 30: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE 30